株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙SALE
市場調査レポート

心的外傷後ストレス障害(PTSD)治療薬の世界市場:2018年〜2022年

Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022

発行 TechNavio (Infiniti Research Ltd.) 商品コード 333551
出版日 ページ情報 英文 116 Pages
即納可能
価格
本日の銀行送金レート: 1USD=109.88円で換算しております。
Back to Top
心的外傷後ストレス障害(PTSD)治療薬の世界市場:2018年〜2022年 Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022
出版日: 2018年03月22日 ページ情報: 英文 116 Pages
概要

心的外傷後ストレス障害(PTSD)治療薬市場について

Technavioのアナリストは、世界の心的外傷後ストレス障害(PTSD)治療薬市場は、2018年から2022年にかけて1.26%のCAGRで成長すると予測しました。

当レポートでは、世界の心的外傷後ストレス障害(PTSD)治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 調査範囲

第3章 調査方法

第4章 市場状況

  • 市場のエコシステム
  • 市場特性
  • 市場セグメンテーション分析

第5章 パイプラインの風景

第6章 市場規模

  • 市場の定義
  • 市場規模
  • 市場規模および予測

第7章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市場状況

第8章 市場セグメンテーション:製品別

  • セグメンテーション:製品別
  • 比較:製品別
  • 抗うつ薬
  • 精神安定剤
  • 他のPTSD治療薬
  • 市場機会:製品別

第9章 顧客情勢

第10章 地域情勢

  • 地域別セグメンテーション
  • 地域比較
  • 南北アメリカ
  • 欧州・中東・アフリカ地域
  • アジア太平洋地域
  • 市場機会

第11章 意思決定の枠組み

第12章 成長要因と課題

  • 市場の成長要因
  • 市場の課題

第13章 市場動向

  • PTSDの新たな治療法
  • 臨床研究に重点を置く製薬企業や機関

第14章 ベンダー情勢

  • 概要
  • 創造的破壊の状況

第15章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck

第16章 付録

  • 略語のリスト
図表
  • Exhibit 01: Parent market
  • Exhibit 02: Global CNS disorders therapeutics market segmentation
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Major pipeline products
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2017
  • Exhibit 08: Validation techniques employed for market sizing 2017
  • Exhibit 09: Global PTSD therapeutics market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 10: Global PTSD therapeutics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 11: Five forces analysis 2017
  • Exhibit 12: Five forces analysis 2022
  • Exhibit 13: Bargaining power of buyers
  • Exhibit 14: Bargaining power of suppliers
  • Exhibit 15: Threat of new entrants
  • Exhibit 16: Threat of substitutes
  • Exhibit 17: Threat of rivalry
  • Exhibit 18: Market condition - Five forces 2017
  • Exhibit 19: Global PTSD therapeutics market - Market share 2017-2022 (%)
  • Exhibit 20: Comparison by product
  • Exhibit 21: Antidepressants market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 22: Antidepressants market - Year-over-year growth 2018-2022 (%)
  • Exhibit 23: Anxiolytics market - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 24: Anxiolytics market - Year-over-year growth 2018-2022 (%)
  • Exhibit 25: Other PTSD therapeutics - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 26: Other PTSD therapeutics - Year-over-year growth 2018-2022 (%)
  • Exhibit 27: Market opportunity by product
  • Exhibit 28: Customer landscape
  • Exhibit 29: Global PTSD therapeutics market - Market share by geography 2017-2022 (%)
  • Exhibit 30: Regional comparison
  • Exhibit 31: PTSD therapeutics market in Americas - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 32: PTSD therapeutics market in Americas - Year-over-year growth 2018-2022 (%)
  • Exhibit 33: Top 3 countries in Americas
  • Exhibit 34: PTSD therapeutics market in EMEA - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 35: PTSD therapeutics market in EMEA - Year-over-year growth 2018-2022 (%)
  • Exhibit 36: Top 3 countries in EMEA
  • Exhibit 37: PTSD therapeutics market in APAC - Market size and forecast 2017-2022 ($ mn)
  • Exhibit 38: PTSD therapeutics market in APAC - Year-over-year growth 2018-2022 (%)
  • Exhibit 39: Top 3 countries in APAC
  • Exhibit 40: Market opportunity
  • Exhibit 41: Vendor landscape
  • Exhibit 42: Landscape disruption
  • Exhibit 43: Vendors covered
  • Exhibit 44: Vendor classification
  • Exhibit 45: Market positioning of vendors
  • Exhibit 46: GlaxoSmithKline - Overview
  • Exhibit 47: GlaxoSmithKline - Business segments
  • Exhibit 48: GlaxoSmithKline - Organizational developments
  • Exhibit 49: GlaxoSmithKline - Geographic focus
  • Exhibit 50: GlaxoSmithKline - Segment focus
  • Exhibit 51: GlaxoSmithKline - Key offerings
  • Exhibit 52: GlaxoSmithKline - Key customers
  • Exhibit 53: Pfizer - Overview
  • Exhibit 54: Pfizer - Business segments
  • Exhibit 55: Pfizer - Organizational developments
  • Exhibit 56: Pfizer - Geographic focus
  • Exhibit 57: Pfizer - Segment focus
  • Exhibit 58: Pfizer - Key offerings
  • Exhibit 59: Pfizer - Key customers
  • Exhibit 60: Eli Lilly and Company - Overview
  • Exhibit 61: Eli Lilly and Company - Business segments
  • Exhibit 62: Eli Lilly and Company - Organizational developments
  • Exhibit 63: Eli Lilly and Company - Geographic focus
  • Exhibit 64: Eli Lilly and Company - Segment focus
  • Exhibit 65: Eli Lilly and Company - Key offerings
  • Exhibit 66: Eli Lilly and Company - Key customers
  • Exhibit 67: H. Lundbeck - Overview
  • Exhibit 68: H. Lundbeck - Business segments
  • Exhibit 69: H. Lundbeck - Organizational developments
  • Exhibit 70: H. Lundbeck - Geographic focus
  • Exhibit 71: H. Lundbeck - Segment focus
  • Exhibit 72: H. Lundbeck - Key offerings
  • Exhibit 73: H. Lundbeck - Key customers
目次
Product Code: IRTNTR21624

About Post-Traumatic Stress Disorder (PTSD)

Post-Traumatic Stress Disorder (PTSD) therapeutics include drugs that are used in the treatment of PTSD.

Technavio's analysts forecast the global post-traumatic stress disorder (PTSD) therapeutics market to grow at a CAGR of 1.26% during the period 2018-2022.

Covered in this report

The report covers the present scenario and the growth prospects of the global post-traumatic stress disorder (PTSD) therapeutics market for 2018-2022. To calculate the market size, the report considers the revenue generated from the sales of post-traumatic stress disorder (PTSD) therapeutics.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Post-Traumatic Stress Disorder (PTSD) Therapeutics Market 2018-2022, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck

Market driver

  • Increasing initiatives by public and private organizations
  • For a full, detailed list, view our report

Market challenge

  • Unmet need for existing therapies
  • For a full, detailed list, view our report

Market trend

  • Emerging therapies for PTSD treatment
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2022 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

PART 03: RESEARCH METHODOLOGY

PART 04: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 05: PIPELINE LANDSCAPE

PART 06: MARKET SIZING

  • Market definition
  • Market sizing 2017
  • Market size and forecast 2017-2022

PART 07: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 08: MARKET SEGMENTATION BY PRODUCT

  • Segmentation by product
  • Comparison by product
  • Antidepressants
  • Anxiolytics
  • Other PTSD therapeutics
  • Market opportunity by product

PART 09: CUSTOMER LANDSCAPE

PART 10: REGIONAL LANDSCAPE

  • Geographical segmentation
  • Regional comparison
  • PTSD therapeutics market in Americas
  • PTSD therapeutics market in EMEA
  • PTSD therapeutics market in APAC
  • Market opportunity

PART 11: DECISION FRAMEWORK

PART 12: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 13: MARKET TRENDS

  • Emerging therapies for PTSD treatment
  • Increasing focus on clinical research by pharmaceutical companies and institutions

PART 14: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption

PART 15: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly and Company
  • H. Lundbeck

PART 16: APPENDIX

  • List of abbreviations
Back to Top